louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00236171: Evaluation of Topical Antipsoriatics in the Psoriasis Plaque Test
Official title: Evaluation of Topical Antipsoriatics in the Psoriasis Plaque Test
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Psoriasis Vulgaris
Keywords: topical therapy
Psoriasis Plaque Test
Lead sponsor: Technische Universität Dresden
Sponsor class: OTHER
First posted: 2005-10-12
Enrollment: 14
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the efficacy of the topical therapies Protopic and Advantan as well as their combination against placebo in a Psoriasis Plaque Test

Detailed description: daily psoriasis plaque tests for two weeks and optical coherence tomography (OCT) and 20-MHz-ultrasound on day 0 and day 11, 10 days post end of treatment and 20 days post end of treatment

Eligibility criteria: Inclusion Criteria:

* Patients older than 18 Years
* Negative urine pregnancy test
* Written informed consent
* Good compliance

Exclusion Criteria:

* Patients less than 18 years
* Pregnant patients
* Patients with renal insufficiency, liver diseases
* Patients who received systemic antipsoriatic treatment or UV treatment less than 4 weeks prior to study
* Patients who used topical antipsoriatics within two weeks prior to study
* Immunosuppressed Patients

Primary outcomes:
measure: sum score of psoriasis plaque tests on day 11
Secondary outcomes:
measure: 20-MHz-ultrasound and OCT on day 11
Other outcomes:
Locations:
city: Dresden
country: Germany
facility: Technische Universität Dresden
state: Sachsen
Study officials:
affiliation: Technische Universität Dresden
name: Gottfried Wozel, Professor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05005871: Comparison of Quadratus Lumborum Intramuscular and Transmuscular in Postoperative Pain
Official title: Comparison of the Effectiveness of Intramuscular and Transmucular Quadratus Lumborum Blocks Quality in Postoperative Pain
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pain, Postoperative
Pain, Acute
Cesarean Section Complications
Lead sponsor: Udayana University
Sponsor class: OTHER
First posted: 2021-08-16
Enrollment: 48
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Acute pain is reported in approximately 80% of patients undergoing postoperative care for various types of surgical procedures in the United States. Another study reported patient postoperative pain intensity with 75% with severe pain in the first 1 to 2 postoperative days and 38% reporting moderate to severe pain at 14 postoperative days. Several modalities have been used as the standard for the management of pain postoperative C-sections.

One of the postoperative analgesic modalities for SC is quadratus lumborum block (QLB). This technique has advantages in relieving postoperative pain after C-section because it is considered to be able to relieve visceral pain as well as somatic pain. The transmuscular QLB (QLBT) approach is one of the most frequently used. This technique was found to be effective with regard to the distribution of analgesics to the paravertebral spaces which is the hallmark of QLB. However, this technique was found to be difficult to perform. Difficulties were reported related to the position of the procedure i.e. lateral or sitting position.


Eligibility criteria: Inclusion Criteria:

* Underwent C-section with subarachnoid block
* Aged 18-35 years old.
* ASA preoperative physical status 1-2

Exclusion Criteria:

* Coagulopathy
* Anatomic abnormalities of the abdomen
* History of allergy to local anesthesia
* History of hyperalgesia
* History of drug abuse (sedatives, opioids, paracetamol, or other pain relievers)
* Require postoperative intensive care
* Refuse to participate in research.

Primary outcomes:
measure: Postoperative pain
timeFrame: Up to 24 hours after surgery
measure: Postoperative morphine requirements
timeFrame: Up to 72 hours after surgery
Secondary outcomes:
Other outcomes:
Locations:
city: Denpasar
country: Indonesia
facility: Sanglah General Hospital
state: Bali
Study officials:
References:
Clinical trial NCT01761071: Time Serial Analysis on Preemptive Analgesia of Preoperative Topical Diclofenac and Ketorolac in Photorefractive Keratectomy(PRK)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Myopes Who Have Undergone PRK.
Lead sponsor: Yonsei University
Sponsor class: OTHER
First posted: 2013-01-04
Enrollment: 94
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The investigators performed this study to investigate pain prevention of preoperative topical nonsteroidal anti-inflammatory drug (NSAID) in photorefractive keratectomy(PRK) using time serial pain scoring.


Eligibility criteria: Inclusion Criteria:

1. at least 19 years of age
2. simultaneous bilateral PRK schedule
3. more than 400μm(including epithelium) of postoperative corneal thickness
4. less than 150μm of ablation depth.

Exclusion Criteria:

1. a history of ocular surgery or trauma
2. two-diopter more difference in spherical equivalent (SE) between the eyes, 3. keratoconus or other corneal pathology

4. use of systemic or topical NSAID within 1 month before the surgery 5. history of allergic reaction to aspirin or other NSAIDs 6. glaucoma or ocular hypertension (\> 20 mmHg) 7. collagen vascular diseases 8. diabetic retinopathy 9. pregnancy or lactation 10. intraoperative complications.

Primary outcomes:
measure: Pain score using visual analog scale(VAS) of each topical NSAIDs pre-treated eyes.
timeFrame: Change the VAS level at 6, 18, 24, 36, 48, 72, and 96 hours after ketorolac in photorefractive keratectomy(PRK)
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Departement of Ophthalmology, Yonsei University College of Medicine
Study officials:
References:
Clinical trial NCT05209971: Macular Thickness and Visual Acuity in Diabetic Hypertensive Patients
Official title: Macular Thickness and Visual Acuity in Diabetic Hypertensive Patients in Sohag City
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Macular Edema
Keywords: Macular thickness and visual acuity
Lead sponsor: Sohag University
Sponsor class: OTHER
First posted: 2022-01-27
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: This is a retrospective study of patients of type 2 diabetes with hypertension

Brief summary: In this study, measurements of central macular thickness using optical coherence tomography along with examination of visual acuity by Snellen's chart in diabetic hypertensive patients will be done .

Detailed description: correlate relationship between optical coherence tomography changes and visual acuity in patients with type 2 diabetes and hypertension

Eligibility criteria: Inclusion Criteria:

* Type 2 diabetic patients with hypertension .

Exclusion Criteria:

* Patients with type 1 diabetes mellitus .
* Ocular disease ( such as high myopia , glaucoma ) .
* Patients with opacities in the media ( corneal opacities , dense cataract , vitreous hemorrhage ) .
* Systemic medication (Tamoxifen , Chloroquine , Canthaxanthine ) to avoid its effect on macular thickness .
* Central visual field defect that prevents fixation on OCT .
* Intraocular inflammation such as anterior or posterior uveitis .
* Refractive error greater than 6 diopter .

Primary outcomes:
measure: macular thickness in diabetic hypertensive patients
timeFrame: June 2022
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: faculty of medicine
name: Raghda Abdelraheem, doctor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01911871: Multicenter Observational Study on Myocardial Iron Overload in 3 Multitransfused Populations
Official title: Multicenter Observational Study on Myocardial Iron Overload in 3 Multitransfused Populations
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Thalassemia
Sickle Cell Disease
Myelodysplasia
Keywords: Thalassemia
sickle cell disease
myelodysplasia
transfusion
chelation
Lead sponsor: Assistance Publique - Hôpitaux de Paris
Sponsor class: OTHER
Collaborators: name: Novartis
First posted: 2013-07-30
Enrollment: 110
Sex: ALL
Minimum age (years): 6
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients affected with thalassemia, SCD, and myelodysplasia

Brief summary: The investigators' primary objective is to study prevalences of myocardial iron overload, defined as a cardiac T2\*\< 20 ms, in 3 populations of multiply transfused patients, affected with thalassemia, sickle cell disease, and myelodysplasia.

Detailed description: The inevestigators' primary objective is to study prevalences of myocardial iron overload, defined as a cardiac T2\*\< 20 ms, in 3 populations of multiply transfused patients, affected with thalassemia, sickle cell disease, and myelodysplasia.

The investigators will record concomitantly parameters which, according to literature data, may influence the occurrence of this complication, and will look for correlations with these parameters and iron overload (secondary objectives), in each of the 3 cohorts.

14 centres are involved and enrol patients with thalassemia, or sickle cell disease, or myelodysplasia having received in the past year \> 8 erythrocyte concentrates, and having had a cardiac MRI. Patients files register the type of the disease, age at the beginning of transfusion and chelation, chelator type and dosage, liver and cardiac T2\*.

Eligibility criteria: Inclusion Criteria:

* Thalassemia, sickle cell disease, myelodysplasia
* having received in the past year \> 8 erythrocyte concentrates
* \> 6 years of age

Exclusion Criteria:

* preexisting cardiac disease

Primary outcomes:
measure: Cardiac T2* (MRI)
timeFrame: Day 0
Secondary outcomes:
measure: Liver T2*(MRI)
timeFrame: Day 0
Other outcomes:
Locations:
city: Paris
country: France
facility: Hôpital Necker Enfants Malades
Study officials:
affiliation: Groupement Hospitalier Necker
name: Mariane de montalembert, MD/PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT04728971: To Evaluate the Efficacy and Safety of Micafungin in Preventing Invasive Mycosis After Liver Transplantation
Official title: To Evaluate the Efficacy and Safety of Micafungin in Preventing Invasive Mycosis After Liver Transplantation
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE4
Conditions: Liver Transplantation
Keywords: Micafungin
Invasive Mycosis
Prevention
Lead sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Sponsor class: OTHER
First posted: 2021-01-28
Enrollment: 200
Sex: ALL
Minimum age (years): 60
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: To evaluate the clinical success rate of micafungin in preventing invasive mycosis after liver transplantation.


Eligibility criteria: Inclusion Criteria:

1. Sign the informed consent form voluntarily;
2. Liver transplant patients with 1 high-risk factor; A. Transplant again; B. Fulminant liver failure; C. Renal failure requires alternative treatment (defined as creatinine clearance ≤40 ml/min); D. ICU duration before liver transplantation≥48h; E. Have received abdominal surgery within one month before liver transplantation or; F. Common bile duct jejunostomy (except for children); G. Excessive blood transfusion (blood transfusion exceeds 2000mL); H. The donor's ICU hospital stay exceeds 5 days; I. Positive sputum and blood culture of the donor J. The donor has evidence of lung or bloodstream infection (pulmonary infection is evaluated according to the diagnostic criteria and treatment principles (draft) of invasive lung fungal infection, and bloodstream infection is evaluated according to invasive fungal disease of patients with hematopathy/malignant tumor Diagnostic criteria and treatment principles (fifth revised edition) for evaluation) K. 60 years old ≤ age ≤ 65 years old

Exclusion Criteria:

1. Have used other investigational drugs or are participating in other clinical trials within 4 weeks before enrollment;
2. Currently combined with any kind of fungal infection;
3. Allergic to study drugs;
4. Joint transplantation;
5. Women who are pregnant, preparing to become pregnant or breast-feeding;
6. The investigator thinks that it is not suitable to use the test drug.

Primary outcomes:
measure: Post-transplant infections
timeFrame: 90 days
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT04012671: A Registered Cohort Study on Duchenne Muscular Dystrophy
Official title: A Registered Cohort Study on Duchenne Muscular Dystrophy
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Duchenne Muscular Dystrophy
Lead sponsor: First Affiliated Hospital of Fujian Medical University
Sponsor class: OTHER
First posted: 2019-07-09
Enrollment: 2000
Sex: ALL
Minimum age (years): 2
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients who are diagnosed as Duchenne Muscular Dystrophy in the hosipital

Brief summary: Dystrophinopathy is a term of X-linked recessive genetic disease, including Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, and the X-linked dilated cardiomyopathy. The aim of this study is to determine the clinical spectrum and natural progression of dystrophinopathy in a prospective multicenter natural history study, to assess the clinical, genetic of patients with dystrophinopathy to optimize clinical management.


Eligibility criteria: Inclusion Criteria:

* Beyond 2 years old
* Diagnosis with Duchenne Muscular Dystrophy, and female carriers, genotypically confirmed
* Diagnosis should be supported by muscle biopsy, if no genetic confirmation.

Exclusion Criteria:

* Presence of other clinically significant illness

Primary outcomes:
measure: Age at death
timeFrame: 20 years
Secondary outcomes:
Other outcomes:
Locations:
city: Fuzhou
country: China
facility: First Affiliated Hospital of Fujian Medical University
Study officials:
References:
Clinical trial NCT00199771: Hypertonic Saline Dextran in Pediatric Cardiac Surgery
Official title: The Use of Hypertonic Saline Dextran in Cardiac Surgery Utilizing Cardio Pulmonary Bypass in Children Less Than 17 Weeks Old.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Heart Defects, Congenital
Transposition of Great Vessels
Heart Septal Defects, Ventricular
Endocardial Cushion Defects
Keywords: Cardiac Surgery
Infant
Infant, Newborn
Hypertonic Solutions
Saline Solution, Hypertonic
Capillary leak
Inflammation Mediators
Lead sponsor: Oslo University Hospital
Sponsor class: OTHER
Collaborators: name: BioPhausia
First posted: 2005-09-20
Enrollment: 14
Sex: ALL
Maximum age (years): 16
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether infusion of hypertonic saline dextran attenuates the inflammatory response and the water overload, during and after major cardiac surgery in small children.

Detailed description: After major cardiac surgery in small children, extravasation of fluid due to increased capillary leak has negative effect on haemodynamics and respiration. Inflammation cascades are activated by surgery and the use of cardio pulmonary bypass (CPB). We want to test whether a small infusion of 7.5% NaCl in 6% dextran solution before and after CPB reduces inflammatory activation by measuring the levels of interleukins 6 and 8 (IL-6, IL-8). We also measure extravascular lung water, fluid balance and weight during the first 24 hours post CPB.

Eligibility criteria: Inclusion Criteria:

* Patients with congenital heart defect undergoing surgery using cardio pulmonary bypass (CPB).
* Age below 17 weeks

Exclusion Criteria:

* Preoperative: organ failure (other than heart), serum sodium \> 155 mmol/l, central venous pressure \> 12 mmHg
* Perioperative: core temperature \< 25 ºC on CPB, re-heparinization, re-operation

Primary outcomes:
measure: IL-6 and IL-8 2 hours post CPB
measure: Extra vascular lung water 2 and 24 hours post CPB
Secondary outcomes:
measure: Fluid balance
measure: Weight gain
measure: Cardiac output
measure: Intrathorasic blood volume
measure: Blood pressure during the first 24 hours post CPB
Other outcomes:
Locations:
Study officials:
affiliation: Oslo University Hospital
name: Gunnar Bentsen, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06746571: Role of Cbc Indices in Acute Lymphoblastic Leukemia Patients
Official title: Role of Cbc Indices in Acute Lymphoblastic Leukemia Patients
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Lymphoblastic Leukemia
Lead sponsor: Sohag University
Sponsor class: OTHER
First posted: 2024-12-24
Enrollment: 100
Sex: ALL
Minimum age (years): 5
Maximum age (years): 50
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: CROSSOVER
Primary purpose: DIAGNOSTIC

Brief summary: Role of cbc indices in acute lymphoblastic leukemia patients to explore the prognostic role of them in prediction the response to induction chemotherapy

Detailed description: Role of neutrophil to lymph ratio , lymphocyte to monocyte ratio and platelet to lymphocyte in acute lymphoblastic leukemia adults and pediatric patients to explore the prognostic role of them in prediction the response to induction chemotherapy

Eligibility criteria: Inclusion Criteria:

* patients newly diagnosed ALL

Exclusion Criteria:

* others malignanices
* ALL on therapy

Primary outcomes:
measure: neutrophil to lymphocyte ratio
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Sohag
country: Egypt
facility: Sohag university Hospital
Study officials:
References:
citation: Jiang Z, Dong Z, Wang L, Jiang W. Method for Diagnosis of Acute Lymphoblastic Leukemia Based on ViT-CNN Ensemble Model. Comput Intell Neurosci. 2021 Aug 21;2021:7529893. doi: 10.1155/2021/7529893. eCollection 2021.
citation: Gavralidis A, Brunner AM. Novel Therapies in the Treatment of Adult Acute Lymphoblastic Leukemia. Curr Hematol Malig Rep. 2020 Aug;15(4):294-304. doi: 10.1007/s11899-020-00591-4.
citation: Haider RZ, Ujjan IU, Khan NA, Urrechaga E, Shamsi TS. Beyond the In-Practice CBC: The Research CBC Parameters-Driven Machine Learning Predictive Modeling for Early Differentiation among Leukemias. Diagnostics (Basel). 2022 Jan 7;12(1):138. doi: 10.3390/diagnostics12010138.
citation: Stefaniuk P, Szymczyk A, Podhorecka M. The Neutrophil to Lymphocyte and Lymphocyte to Monocyte Ratios as New Prognostic Factors in Hematological Malignancies - A Narrative Review. Cancer Manag Res. 2020 Apr 29;12:2961-2977. doi: 10.2147/CMAR.S245928. eCollection 2020.
Clinical trial NCT01493271: A Study of RO5093151 in Patients With Ocular Hypertension Or Open Angle Glaucoma
Official title: An Adaptive, Multi-center, Randomized, Investigator-masked, Subject-masked, Multiple-dose, Placebo-controlled, Parallel Study to Investigate Efficacy, Safety, Tolerability and Pharmacokinetics of RO5093151 for up to 28 Days in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Hypertension, Glaucoma, Open-Angle
Lead sponsor: Hoffmann-La Roche
Sponsor class: INDUSTRY
First posted: 2011-12-15
Enrollment: 31
Sex: ALL
Minimum age (years): 21
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This randomized, double-blind, placebo-controlled, multi-center study will evaluate the safety and the effect of RO5093151 on intraocular pressure in patients with ocular hypertension or open angle glaucoma. Patients will be randomized to receive oral doses of RO5093151 or placebo twice daily. The anticipated time on study treatment is 7 days with the possibility to extend to 28 days.


Eligibility criteria: Inclusion Criteria:

* Adult patients, at least 21 years of age, inclusive
* Diagnosis of ocular hypertension or primary open angle glaucoma in at least one eye
* Able to participate and willing to give informed consent

Exclusion Criteria:

* Presence of extreme narrow angle with complete or partial closure
* Progressive retinal or optic nerve disease from any cause other than glaucoma
* History or signs of penetrating ocular trauma
* Uncontrolled hypertension
* Clinically significant abnormalities in laboratory test results
* Positive test results on hepatitis B, hepatitis C, or HIV 1 and 2
* Kidney disease or dysfunction

Primary outcomes:
measure: Change in mean intraocular pressure (IOP) at 1 hour post-dose following 7 days of treatment
timeFrame: Day 7
Secondary outcomes:
measure: Change in mean daily intraocular pressure (IOP)
timeFrame: Up to 28 days
measure: Change in mean intraocular pressure (IOP) at each assessment time-points
timeFrame: Up to 28 days
measure: Change in intraocular pressure (IOP) during a placebo lead-in phase
timeFrame: 7 days
measure: Pharmacokinetics (area under the concentration time curve)
timeFrame: Day 7
measure: Urinary ratio of tetrahydrocortisol to tetrahydrocortisone
timeFrame: 7 days
measure: Safety (incidence of adverse events)
timeFrame: Up to 28 days
Other outcomes:
Locations:
city: Morrow
country: United States
state: Georgia
city: High Point
country: United States
state: North Carolina
city: Mt. Pleasant
country: United States
state: South Carolina
city: Sofia
country: Bulgaria
city: Hradec Kralove
country: Czech Republic
city: Litomysi
country: Czech Republic
city: Praha
country: Czech Republic
city: Usti Nad Labem
country: Czech Republic
city: Zlin
country: Czech Republic
city: Budapest
country: Hungary
city: Budapest
country: Hungary
city: Esztergom
country: Hungary
Study officials:
affiliation: Hoffmann-La Roche
name: Clinical Trials
role: STUDY_DIRECTOR
References: